My colleague haematologist Ken Romeril of Myeloma NZ has an excellent article on stuff today calling out Pharmac and the new cancer agency on their failure to factor blood cancers into their plans.

Read it here.

Efforts to target key mechanisms in the development of chronic lymphocytic leukemia (CLL), one of the most common lymphoid cancers, have led to several new treatments. Among these, ibrutinib emerged as a strong approach for patients who were too frail for aggressive treatment.¹ But for healthier patients with CLL, the benefit of this drug remained unknown for a time.

A phase 3 study published in the New England Journal of Medicine showed a benefit for ibrutinib plus rituximab for these more fit patients.² Although the data help clarify the potential role of ibrutinib in CLL, they also raise difficult questions about the future of this treatment approach.

The standard first-line treatment for otherwise healthy CLL patients 70 years or younger has been a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab (FCR). Patients with immunoglobulin heavy-chain variable region (IGHV)-mutated disease had particularly good results with this treatment: roughly half remained progression-free for up to 8 years after initial treatment. However, substantial toxic effects in the aftermath of treatment, including myelosuppression, risk of myelodysplasia, and infectious complications, have led researchers to explore other avenues of therapy — in particular, ibrutinib.

Ibrutinib inhibits Bruton tyrosine kinase (BTK), a B-cell signaling protein involved in B-cell development, differentiation, proliferation, and survival. After studies showed the drug to be effective for patients with relapsed CLL and then frail patients with untreated CLL, researchers have been eager to investigate its role in first-line therapy for younger patients.

Most studies so far have explored the use of ibrutinib as a monotherapy. This trial, however, led by Tait Shanafelt, MD, of Stanford University School of Medicine, California, combined ibrutinib with rituximab, and compared the regimen with the standard treatment of FCR.

The study began with 529 patients, all with previously untreated CLL. A total of 354 patients, all 70 years or younger, were randomly assigned to receive ibrutinib-rituximab treatment, consisting of 1 cycle of ibrutinib, followed by 6 cycles of ibrutinib-rituximab combined, and then ibrutinib alone, taken indefinitely until disease progression. The 175 patients in the control group received 6 cycles of FCR chemoimmunotherapy. The primary end point was progression-free survival (PFS), with overall survival (OS) as the secondary end point.

Patients in the ibrutinib-rituximab group received 1 dose of 420 mg per day of ibrutinib during day 1 to day 28 of each of the 6 cycles, until either their disease progressed or the side effects became intolerable. Alongside this dosage, they also received rituximab, during cycles 2 through 7. The FCR group received 6 cycles of FCR.

At a median follow-up of 33.6 months, Dr Shanafelt and the team found a benefit for the experimental treatment. At that point, 89.4% of patients in the experimental group had experienced no disease progression, compared with 72.9% in the control group. OS rates echoed the benefit: 98.8% of patients in the experimental group were still alive, compared with 91.5% of patients in the control group.

The researchers wondered if treatment efficacy would be different for patients with the IGHV-mutated CLL. Dividing the existing patients into 2 subgroups, they found that for patients carrying the mutation, the 2 protocols were nearly identical — and in fact, FCR proved 0.3% more effective. For those without the mutation, however, the ibrutinib-rituximab combination was superior to FCR: with 90.7% PFS at 3 years, compared with 62.5%, respectively. Patients in the experimental group without IGHV-mutated disease also experienced fewer serious infections.

Researchers concluded that treatment with ibrutinib-rituximab was superior to FCR with regard to both PFS and OS. They reported a 65% lower risk of progression and an 83% lower risk of death. This superior PFS was also present in high-risk subgroups, including patients with Rai stage III or stage IV disease, chromosome 11q22.3 deletion, and unmutated IGHV.

Study coauthor Jacqueline Claudia Barrientos, MD, associate professor at the Feinstein Institutes for Medical Research in New York, emphasized that the study does not provide any evidence that the addition of rituximab improved outcomes or remission duration beyond what is achieved by ibrutinib alone. Because the study didn’t include an ibrutinib-monotherapy arm, there’s no way to know. “I don’t believe that we should move to using combination ibrutinib plus rituximab for frontline except in specific cases, such as uncontrolled autoimmune complications or in a patient with a very aggressive disease that requires combined therapy because monotherapy is taking too long to work,” Dr Barrientos said.

She also pointed out that widespread use of ibrutinib as a frontline treatment would raise several issues. Although ibrutinib appears to cause less myelosuppression than FCR, she said, “there are still other issues that can affect quality of life.” These include bleeding, joint pain, diarrhea, cardiac arrhythmias, and other side effects. Dr Barrientos noted that because ibrutinib needs to be taken indefinitely, sorting out these complications is vital.

Cost is another concern. Again, the long-term nature of ibrutinib therapy is the issue: the drug may be too expensive to sustain treatment. In a 2015 paper in the Journal of Oncology Practice, Dr Shanafelt discussed the potential financial burden that would confront the movement toward novel targeted agents, such as ibrutinib, for frontline treatment of CLL.³ This shift, Dr Shanafelt wrote, “will dramatically increase individual out-of-pocket and societal costs of caring for patients with CLL. These cost considerations may undermine the potential promise of these agents by limiting access and reducing adherence.”

Nitin Jain, MD, associate professor of medicine at MD Anderson Cancer Center, Houston, Texas, who was not involved with the study, was optimistic about the findings. The results, he said, were not just statistically significant but also clinically significant.  “This study establishes a new treatment paradigm for younger patients with CLL,” he says. However, he emphasized that this benefit is restricted to patients with IGVH-unmutated disease, per the study findings.

As Dr Jain sees it, the study is just one more piece of the puzzle showing how ibrutinib and new drugs may best benefit patients with CLL. “Several ongoing randomized studies are evaluating combinations of targeted therapies with chemoimmunotherapy,” Dr Jain noted. “The results of these studies will further help define the optimal frontline approach for patients with CLL.”

Disclosure: The study was supported by the National Cancer Institute and Pharmacyclics. Some of the authors of the study reported receiving payments from the pharmaceutical industry. For a full list of disclosures, please refer to the original study.

References

1. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425-2437.
2. Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib–Rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432-443.
3. Shanafelt TD, Borah BJ, Finnes HD, et al. Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels. J Oncol Pract. 2015;11(3):252-258.

This article was originally published on BioSpace

Blood cancer is actually a term applied to three different types of cancer – leukemia, lymphoma and myeloma. For centuries, these cancers had virtually no possibility of survival. Even as recently as the 1960s, the five-year survival rate for leukemia was 14%. By 2010, it had increased to 61%. Similar gains have been made in the survival rates for lymphoma and myeloma, with Hodgkin lymphoma reaching a five-year survival rate of 88% in that year. The story of the science behind the gains in survival rates and the development of ever-more effective therapies is the story of advances in the field of immunotherapy and personalized medicine taking place at centers such as Abramson at UPENN and Dana-Farber in Boston.

Bone Marrow Transplants

The first significant increases in survival rates occurred in the early 1980s, with the introduction of chemotherapy and bone marrow transplants. In a UPENN CureTalks interview in 2017, Dr. Carl June of UPENN described the two-step process. First, the patient’s immune system received super-lethal doses of chemotherapy. Then, bone marrow from a sibling was transplanted into the patient. When the result was a better survival rate, the increase in survival was attributed to the super-lethal dose of chemotherapy administered prior to the transplant. When the procedure was performed on identical twins and researchers discovered that increased survival did not occur, researchers had to rethink their premise. They realized that the source of the survival increase lay in the differences in the marrow of the non-identical sibling rather than in the process of destroying the patient’s immune system before the introduction of new bone marrow.

This better understanding of the cause of increased survival rates from bone marrow transplant therapy, combined with the significant downside arising from graft vs host disease, led June to explore the possibility that patients could receive the benefits of a bone marrow transplant without an actual transplant. He studied the possibility that a patient’s own immune system could be used as a weapon. The outcome of this work was the development of CAR-T cells, approved for use by the FDA in 2017.

CAR-T

CAR-T therapy is the first personalized cancer therapy to be approved by the FDA. The process has been licensed by Novartis. They have manufactured CAR-T cells for patients in their FDA-approved facility. With CAR-T, a patient’s own T-cells are filtered, along with white blood cells, through the leukapheresis process. A viral vector is used to recognize the targeted cells – cells with cancer and other cells expressing a specified antigen. These “reprogrammed” cells are then introduced back into the patient’s blood.

According to June, it is not at all uncommon for a high fever to occur during the time when the CAR-T cells are annihilating the cancer cells. This fever has shown no lasting effect. It is a side effect that indicates that the process is working. For two of the first three participants in the clinical trials held at Penn in 2010, the survival rate for chronic lymphocytic leukemia (CLL) was eight years as of 2018.

Immune Checkpoint Inhibitors

Another FDA-approved immunotherapy agent is used in patients with recurring Hodgkin lymphoma (HL). The FDA approval occurred in 2016, but a study underway in 2019 at Dana-Farber by Dr. Margaret Shipp’s team is investigating the mechanism that causes two proteins, PD-L1 and PD-L2, to overproduce on HL cells. They’ve found that the proteins work with a protein on the T-cells that keeps the T-cells from attacking the HL. By blocking PD-1, it is possible to expose the HL to the T-cells. The use of these checkpoint inhibitors holds promise for those with HL that has reoccurred or not responded to the first therapy.

BiTE

Until recently, a patient’s immune system was reprogrammed to fight a single target – an antigen. Dr. Daniel D’Angelo of Dana-Farber describes BiTEs (bispecific antibodies) as a way to cut out the middle step. Rather than attack first one, and then the other, the BiTE attaches to both a T-cell and a tumor cell at the same time. This FDA-approved therapy is being used to treat acute lymphoblastic leukemia (ALL) but shows potential for the treatment of other cancers.

The potential advantage of BiTEs over CAR-T cell therapy lies in the fact that BiTEs are not patient-specific: There is not the need to remove and reprogram T-cells for reintroduction into the patient’s blood. Currently, BiTE is being used with patients who have multiple myeloma (MM) and have relapsed. Early results are promising. In one clinical trial, some patients showed no trace at all of cancer after treatment. The next step is to see how long this remains the case, as well as whether or not different delivery times or the use of BiTE in conjunction with CAR-T will make a difference in the outcome.

Under Study

At the ASH Annual meeting held at Abramson Cancer Center, two new studies were described.

One study is designed to determine the best time to introduce CAR-T therapy in multiple myeloma (MM). It will identify T-cell biomarkers that help to predict the outcome from CART-BCMA therapy (Abstract #1974 and Abstract #1886). The other explores the combination of CAR-T cells and the tyrosine kinase inhibitor ibrutinib in chronic lymphocytic leukemia (CLL). Initial results show that the use of both in combination will lead to deep and sustained remission (Abstract #298).

The current work is already leading to new avenues of investigation. Improved blood cancer therapies are one part of the advances being made in targeted, personalized therapies.

This article was originally published on the Cancer Network

In the first-line setting, ibrutinib plus rituximab had a superior survival benefit to standard chemoimmunotherapy for patients with chronic lymphocytic leukemia (CLL), according to an interim analysis of a phase III randomized clinical trial published in the New England Journal of Medicine.

Study researchers also noted that “indefinite” use of ibrutinib therapy has been associated with “substantial expense.” According to the IBM Micromedex, the estimated average wholesale price per month for ibrutinib alone is more than $13,324. A 2018 study found that at current prices, ibrutinib was not cost-effective as first-line treatment for CLL patients older than 65 years of age with a 17p deletion.

The trial enrolled 529 patients between March 2014 and June 2016 who were 70 years of age or younger with treatment-naïve CLL. Patients were randomly assigned in a 2:1 ratio to receive either 6 cycles of ibrutinib plus rituximab followed by continuous administration ibrutinib until disease progression (n=354) or 6 cycles of standard chemoimmunotherapy (n=175), which consisted of fludarabine, cyclophosphamide, and rituximab. Follow-up was a median of 33.6 months.

At 3 years, patients who received ibrutinib plus rituximab had a statistically higher progression-free survival (PFS) rate and 65% lower risk of disease progression or death compared with patients who received standard chemoimmunotherapy (89.4% vs 72.9%; HR=0.35; 95% CI, 0.22–0.56; P<0.001). Patients who received ibrutinib plus rituximab also had a significantly higher overall survival (OS) rate and an 83% lower risk of death compared with patients who received standard chemoimmunotherapy (98.8% vs 91.5%; HR=0.17; 95% CI, 0.05–0.54; P<0.001).

Overall, both the ibrutinib plus rituximab and chemoimmunotherapy groups had approximately an 80% incidence of adverse events of grade 3 or higher. There was, however, a difference in infection complications of grade 3 or higher, with the ibrutinib plus rituximab group having a lower incidence compared with the chemoimmunotherapy group (10.5% vs 20.3%; P<0.001).

The incidence of adverse events of grade 3 or higher (regardless of attribution) was similar in the two groups (in 282 of 352 patients [80.1%] who received ibrutinib–rituximab and in 126 of 158 [79.7%] who received chemoimmunotherapy), whereas infectious complications of grade 3 or higher were less common with ibrutinib–rituximab than with chemoimmunotherapy (in 37 patients [10.5%] vs. 32 [20.3%], P<0.001).

“I don’t think one hundred percent of people should be getting ibrutinib as frontline therapy,” Joshua Brody, MD, director of the Lymphoma Immunotherapy Program at the Icahn School of Medicine at Mount Sinai Hess Center for Science and Medicine in New York, told Cancer Network.

On the basis of the study results, he explained the ibrutinib combination is “definitely” a “reasonable” option and “better” than fludarabine, cyclophosphamide, and rituximab, but it’s not “definitely” better than rituximab plus bendamustine, which is the other chemoimmunotherapy regimen commonly used in this patient population.

A previously published trial in treatment-naive CLL patients found a PFS benefit among those who received ibrutinib monotherapy or ibrutinib plus rituximab when compared with rituximab plus bendamustine. However, no OS benefit was seen for the ibrutinib-containing regimens.

This article was originally published on Dana-Farber Cancer Institute

Chemoimmunotherapy combined with a targeted drug given for two years has achieved undetectable minimal residual disease (MRD) for a high proportion of younger patients with chronic lymphocytic leukemia (CLL), Dana-Farber scientists report.

The phase 2 clinical trial results are so favorable that they represent a step toward “a new standard of care with curative potential for a broad population of younger, fit patients” with CLL, say the investigators, led by Matthew Davids, MD, MMSc, and Jennifer Brown, MD, PhD. “Younger” in this setting is 65 years of age or below.

The report in The Lancet Haematology describes the regimen administered to 85 patients with CLL whose median age was 55 years. The study looked at individuals whose cancer carried a mutated IGHV gene — which confers a higher likelihood of a long-lasting response to chemotherapy — and those with an unmutated IGHV gene — who rarely have durable responsesto chemotherapy.

The study examined the combined effect of two different treatment options for CLL patients. The first, chemoimmunotherapy consisting of fludarabine, cyclophosphamide, and rituximab (FCR), can improve overall survival for younger fit patients with CLL who have an IGHV mutation. The second, the targeted drug ibrutinib, can be effective for CLL patients irrespective of their IGHVstatus, but requires continuous treatment. The clinical trial examined if FCR plus time-limited ibrutinib could achieve long-lasting responses in younger, fit patients with either mutational status.

The patients, who were previously untreated, received oral ibrutinib for seven days, then up to six 28-day cycles of FCR along with continuous ibrutinib. Responders continued on maintenance ibrutinib for up to two years, and those who had undetectable MRD in bone marrow after two years were able to stop treatment.

Thirty-three percent of patients achieved the primary endpoint — a complete response with undetectable minimal residual disease in bone marrow two months after the last cycle of ibrutinib plus FCR. A best response of undetectable minimal residual disease in bone marrow was achieved by 84 percent of patients at any time during the study. “Many of the patients had deepening responses while on the two years of ibrutinib maintenance, so later converted to undetectable MRD,” explains Davids.

The researchers say the results of the trial demonstrated that the combination of chemotherapy and two years of ibrutinib maintenance leads “to the best of our knowledge, to the highest proportion of patients achieving undetectable minimal residual disease in the bone marrow ever published for any regimen used to treat this disease.” The approach, they add, could increase the potential to “functionally cure patients with mutated IGHV and, importantly, might for the first time extend this potential to patients with unmutated IGHV.”